Original Research
Pharmaceutical situation of the pharmacological treatment of hospitalized patients with COVID-19 in Libya
Hudam A.M. Elhouni and Sarah A. Shabu
Abstract :
By January 2020, severe acute respiratory syndrome coronavirus-2 has spread internationally to a pandemic that mainly targets the respiratory system. The relevant infectious disease has been identified as coronavirus disease-2019 (COVID-19) by the World Health Organization and declared as a global pandemic. In Libya, the National Center for Disease Control reported the first case of coronavirus disease 2019 on 24th March, 2020. The authorities decided to close borders and activate designated treatment centers to deal with COVID-19 cases and contain the outbreak of SARS-COV-2. This study aimed to assess and evaluate the pharmaceutical situation of medications used in the pharmacological management of hospitalized COVID-19 patients in Tripoli, Libya. Three WHO availability indicators were selected to be studied and reported. A comprehensive list of medicines used in the management of hospitalized COVID-19 patients was constructed after reviewing and comparing seven national and international pharmacological management protocols and guidelines for hospitalized COVID-19 patients. This comparison revealed that nearly 50 medications are intended for use in COVID-19 inpatient pharmacological management. They all agreed on the use of three medications, representing one from each main class. This list was used to cross-check their availability at the chosen designated COVID-19 treatment center. This study proved that the local treatment center’s protocol is more in line with international guidelines than the national treatment guideline. The latter was issued in March 2020. The Libyan National Essential Medicines’ List contained 25 out of 50 medications in the comprehensive list based on the last update in April 2019. This study recommends that national treatment guidelines and National Essential Medicines list require updating. Not all medications used in COVID-19 inpatient management were available in local treatment centers, although, the Emergency Management Department of the Ministry of Health in Libya is responsible for the supply of the required medical supplies and medications to the COVID-19 treatment centers.
References
1. He F, Deng Y, Li W (2020) Coronavirus disease 2019: What we know? Journal of Medical Virology. 92 (7): 719-725. doi: 10.1002/jmv.25766
2. Ludwig S, Zarbock A Z (2020) Coronaviruses and SARS-CoV-2: A brief overview. Anesthesia and Analgesia. 131 (1): 93-96. doi: 10.1213/ANE.0000000000004845
3. World Health Organization. Novel Coronavirus (2019-nCoV) situation report-22. WHO, Feb 2020.
4. World Health Organization. WHO operational package for assessing, monitoring and evaluating country pharmaceutical. Geneva: WHO Press, 2007.
5. World Health Organization. World Health Organization Model List of Essential Medicines 22nd. Geneva: World Health Organization, 2021.
6. Joint Formulary Committee, British National formulary 81. London: Pharmaceutical Press, 2021. Titters of Health. Available at https://www.covid19 treatmentguidelines.nih.gov/. Accessed [25.10.2021].
7. National center of disease control. NCDC Manual for Novel COVID 19 (Management and Treatment). National center of disease control. [Online] March 2020. [Cited: 25 October 2021] https://ncdc.org.ly/ Ar/publications/ 7_5_2020-2/. Accessed [25.10.2021].
8. World Health Organization. Therapeutics and COVID-19: Living guidance. [Online] November 20, 2020. [Cited: December 18, 2021.] https://app.magicapp.org/#/guideline/nBkO1E/section/Egz0xn. Accessed [25.10.2021].
9. Manabe T, Kambayashi D, Akatsu H, Kudo K (2021) Favipiravir for the treatment of patients a systematic review and meta-analysis. BMC Infectious Diseases. 21 (1): 489. doi: 10.1186/s12879-021-06164-x
10. Singhal T (2020) a review of coronavirus disease-2019 (COVID-19). Indian Journal of Pediatric. 87: 281-286. doi: 10.1007/s12098-020-03263-6
Citation :
Elhouni HAM, Shabu SA (2022) Pharmaceutical situation of the pharmacological treatment of hospitalized patients with COVID-19 in Libya. Mediterr J Pharm Pharm Sci. 2 (1): 87-94. [Article number: 57]. https://doi.org/10.5281/zenodo.6399936